Lucid Capital Markets
Tracked across 3 events · 25 articles · First seen Apr 14, 2026 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at $3.50 per share. The offering is expected to generate approximately $20.0 million in…
Impact: Lucid Capital Markets, LLC is acting as a joint bookrunning manager for the public offering by NRx Pharmaceuticals, assisting in the sale of shares.
Jun 02, 2026 · 10 articles
Business
Flow Capital Corporation (FSK) announced the pricing and subsequent completion of a public offering of $900 million in 7.500% unsecured notes due 2031. The notes will mature on August 1, 2031, and can be redeemed…
Impact: Lucid Capital Markets, LLC acted as a co-manager for the offering.
Jun 02, 2026 · 8 articles
Business
Impact: Lucid Capital Markets provided a fairness opinion to Galera Therapeutics' Board of Directors.
Apr 14, 2026 · 7 articles
60
Lucid Capital Markets acted as joint manager NRx PharmaceuticalsNRx Pharmaceuticals Prices...
NEWSDESK
Track Lucid Capital Markets live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard